Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medivolve Inc MEDVF

Medivolve Inc. is a Canadian healthcare technology company. The Company and its subsidiaries, Medivolve Pharmacy Inc. (doing business as Marbella Pharmacy) and Kedy Ying Jao D.O., a Medical Corporation, operate a distributed network of two retail patient-care locations in California, United States. It has two business units: Medivolve Pharmacy Division (MPD) and Medivolve Clinic Services Division (MCSD). MPD provides retail pharmacy and mail-order pharmacy services related to COVID-19, antibiotics, dermatology, family medicine, immunology, neurology, pain management, pediatrics, preventive medicine and psychiatry to patients in Southern California. MCSD provides licensed healthcare through a clinic in Brea, California, United States. MCSD is focused on developing a telehealth platform, which connects patients with physicians, and facilitates and manages the provision of virtual consultation, diagnosis, and treatment services in partnership with qualified health practitioners.


OTCPK:MEDVF - Post by User

Comment by Jasper66on Oct 22, 2020 4:51pm
107 Views
Post# 31766333

RE:RE:RE:RE:Expect Huge News Release

RE:RE:RE:RE:Expect Huge News Release
A lot of us share your frustration. Some companies stock price rises on spec of potential earnings while others have to have the revenue for shareholders can see the value. With the business of Covid, I guess it hard for investors to see the revenue potential cause we hear of a potential vaccine every day. So the question becomes, why would I invest on Qsc when the vaccine is right around the corner. The reality is that a vaccine good enough for the world is not going to be found in the near future. We also have the Annonomous parasite that has been here since July or possibly earlier. So I put Qsc in the category of having to prove by showing revenue before we see the price increase significantly.
<< Previous
Bullboard Posts
Next >>